In contrast, recent meta-analyses of randomized control trials indicate the lack of signals related to the increase in the risk of pancreatic and breast cancer, in subjects treated with GLP-1 RAs either for T2D or for obesity [133]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.